Semaglutide received FDA clearance for adolescent use (ages 12+) in late 2023, but only for patients with severe obesity and significant metabolic or cardiovascular risk factors, and always under strict medical supervision
But people like that exist to inspire you to do more
According to MedPage Today, 10-15% of patients do not respond adequately to semaglutide, though for many others, the issue isn't non-response but diminished response over time
Even though Innovacer said an IPO isnt on its to-do list, I think bankers could change CEO Abhinav Shashanks mind
doi: 10.3390/immuno1020007 193 BokhariSMZHamarP
Evidence-based treatments for erectile dysfunction include PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil), lifestyle modifications, and specialist interventions